PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients

September 13, 2019 updated by: Yi Zhang, MD, Massachusetts General Hospital
The purpose of this study is to see if the spine shows areas of inflammation using a specific type of imaging (pictures).

Study Overview

Status

Completed

Conditions

Detailed Description

The purpose of this study is to determine if inflammation around the spinal nerves can be identified using a radioactive tracer [11C] PBR28 and integrated PET/MRI scan for the purpose of better treating patients who have radicular lumbar pain with epidural steroid injections.

Study Type

Observational

Enrollment (Anticipated)

42

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • MGH Center for Translational Pain Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  1. Subject is currently diagnosed with lower extremity radicular/sciatica pain.
  2. Healthy subjects with no pain from the local community.

Description

Inclusion criteria for pain subjects:

  1. Subject is 18-75 years old.
  2. Subject is able to give written informed consent.
  3. Subject is currently diagnosed with lower extremity radicular pain regardless of specific or suspected etiologies.
  4. Subject has a clear dermatomal distribution of the painful area extending to the distal lower extremities.
  5. Subject reports ongoing pain intensity of 4 or greater using the visual analogue scale (VAS) during the week prior to enrollment.

Inclusion criteria for healthy subjects:

  1. Subject is 18-75 years old.
  2. Subject is able to give written informed consent.
  3. Subject has no history of chronic back/spine pain.

Exclusion criteria for all groups:

  1. Subject recently received a lumbar ESI (within 8 weeks).
  2. Subject starts new NSAID medication for pain during the study.
  3. Subject has predominantly axial low back pain.
  4. Subject has known pain condition secondary to hip joint arthritis.
  5. Subject is pregnant or breastfeeding.
  6. Subject has allergy to lidocaine.
  7. Subject is treated with chronic corticosteroid therapy.
  8. Subject is on anticoagulation therapy (i.e. Coumadin, Plavix, or Lovenox).
  9. Subject has a known bleeding disorder (i.e. hemophilia).
  10. Subject has uncontrolled high blood pressure [>170/100].
  11. Subject has a known heart condition.
  12. Subject has known inflammatory disease (i.e. inflammatory bowel disease; ankylosing spondylitis; etc.).
  13. Subject has known liver dysfunction or renal insufficiency or impaired elimination (Renal dysfunction is defined as eGFR < 60. Hepatic dysfunction is defined as LFTs ≥ 3x ULN).
  14. Subject has been hospitalized recently (within one month) for a major psychiatric disorder (i.e. major depression, bipolar disorder, schizophrenia, anxiety disorder, or psychosis).
  15. Subject has contraindications to MRI and PET scanning (i.e. presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, or claustrophobia).
  16. Subject had research-related radiation exposure in the last 12 months.
  17. Subject tests positive for use of illicit drugs, marijuana, or non-prescribed drugs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy

Healthy subjects with no pain.

  • Radioactive dye
  • PET/MRI
  • Blood draw
The radioactive dye [11C]PBR28 will be administered through an intravenous line (IV).
Other Names:
  • [11C]PBR28
All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
Other Names:
  • Integrated MR-PET 3 Tesla scanner (Siemens Biograph mMR).
Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
Sciatica

Subjects with sciatica and scheduled for an epidural steroid injection (ESI).

  • Radioactive dye
  • PET/MRI
  • Blood draw
The radioactive dye [11C]PBR28 will be administered through an intravenous line (IV).
Other Names:
  • [11C]PBR28
All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
Other Names:
  • Integrated MR-PET 3 Tesla scanner (Siemens Biograph mMR).
Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inflammation in the spine
Time Frame: 2 hours
The presence of inflammation in the spine using the radioactive tracer [11C]PBR28.
2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Scores on the Visual Analog Scale (VAS)
Time Frame: up to 3 months
The subject's pain score (VAS) at baseline and up to 3 months after the ESI treatment.
up to 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yi Zhang, MD, PhD., Massachusetts General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2014

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

April 24, 2014

First Submitted That Met QC Criteria

May 1, 2014

First Posted (Estimate)

May 5, 2014

Study Record Updates

Last Update Posted (Actual)

September 16, 2019

Last Update Submitted That Met QC Criteria

September 13, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sciatica

Clinical Trials on Radioactive dye

3
Subscribe